Long-term Survival Analysis of Patients with Non-small Cell Lung Cancer Complicated with Type 2 Diabetes Mellitus

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2020 Mar 20

PMID 32190995

Citations 5

Authors

Gaoxiang Wang

Xuejiao Li

Ran Xiong

Hanran Wu

Meiqing Xu

Mingran Xie

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the effect of type 2 diabetes mellitus on survival of patients with non-small cell lung cancer (NSCLC).

Methods: We retrospectively analyzed NSCLC patients who had undergone radical lung cancer surgery from January 2011 to December 2014 in the Anhui Medical University affiliated Anhui Provincial Hospital. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models were used to describe the effect of type 2 diabetes mellitus on the overall survival of patients with NSCLC.

Results: A total of 769 patients with NSCLC were enrolled, including 126 in the diabetic mellitus group and 643 in the nondiabetic mellitus group. The one, three, and five-year survival for patients with and without diabetes mellitus were 86.1% versus 89.6%, 49.5% versus 62.4%, and 33.3% versus 40.6%, respectively. The Cox model showed that type 2 diabetes mellitus was a poor independent prognostic factors for NSCLC patients. In addition, metformin is a good independent prognostic factor for patients with non-small cell lung cancer with type 2 diabetes mellitus.

Conclusions: NSCLC patients without type 2 diabetes mellitus have an increased survival rate compared with those with type 2 diabetes mellitus.

Citing Articles

Is a high preoperative HbA1c level a risk factor for postoperative complications in patients with non-small-cell lung cancer?.

Uramoto H, Mizoguchi T, Motono N J Cardiothorac Surg. 2024; 19(1):364.

PMID: 38915109 PMC: 11194957. DOI: 10.1186/s13019-024-02912-7.

[Clinical Efficacy Analysis of Wedge Resection of Pulmonary  in Patients with Small Volume Invasive Lung Adenocarcinoma].

Cui S, Wang G, Huang Z, Wu M, Wu H, Zhou H Zhongguo Fei Ai Za Zhi. 2024; 27(5):359-366.

PMID: 38880923 PMC: 11183310. DOI: 10.3779/j.issn.1009-3419.2024.102.17.

Changes in target ability of nanoparticles due to protein corona composition and disease state.

Xu W, Xu M, Xiao Y, Yu L, Xie H, Jiang X Asian J Pharm Sci. 2022; 17(3):401-411.

PMID: 35782324 PMC: 9237596. DOI: 10.1016/j.ajps.2022.03.002.

Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163.

Qiu C, Li C, Zheng Q, Fang S, Xu J, Wang H Bioengineered. 2022; 13(5):11987-12002.

PMID: 35603556 PMC: 9275981. DOI: 10.1080/21655979.2021.2005981.

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Small Cell Lung Cancer.

Liao K, Hung C, Shu C, Lee H, Wei Y Int J Chron Obstruct Pulmon Dis. 2021; 16:3255-3262.

PMID: 34880609 PMC: 8645948. DOI: 10.2147/COPD.S328938.

References

Noto H, Goto A, Tsujimoto T, Noda M . Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7(3):e33411. PMC: 3308971. DOI: 10.1371/journal.pone.0033411. View

Zhang Z, Li S . The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(8):707-10. DOI: 10.1111/dom.12267. View

Jeong S, Choi P, Yi J, Yoon S . Impact of Lifestyle Diseases on Postoperative Complications and Survival in Elderly Patients with Stage I Non-Small Cell Lung Cancer. Korean J Thorac Cardiovasc Surg. 2017; 50(2):86-93. PMC: 5380200. DOI: 10.5090/kjtcs.2017.50.2.86. View

Nieminen A, Eskelinen V, Haikala H, Tervonen T, Yan Y, Partanen J . Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci U S A. 2013; 110(20):E1839-48. PMC: 3657814. DOI: 10.1073/pnas.1208530110. View

Quinn B, Dallos M, Kitagawa H, Kunnumakkara A, Memmott R, Hollander M . Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013; 6(8):801-10. PMC: 3740378. DOI: 10.1158/1940-6207.CAPR-13-0058-T. View

Tseng C . Metformin and lung cancer risk in patients with type 2 diabetes mellitus. Oncotarget. 2017; 8(25):41132-41142. PMC: 5522244. DOI: 10.18632/oncotarget.17066. View

Bartling B, Simm A, Sohst A, Silber R, Hofmann H . Effect of diabetes mellitus on the outcome of patients with resected non-small cell lung carcinoma. Gerontology. 2011; 57(6):497-501. DOI: 10.1159/000323856. View

Kalender A, Selvaraj A, Kim S, Gulati P, Brule S, Viollet B . Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5):390-401. PMC: 3081779. DOI: 10.1016/j.cmet.2010.03.014. View

Kourelis T, Siegel R . Metformin and cancer: new applications for an old drug. Med Oncol. 2011; 29(2):1314-27. DOI: 10.1007/s12032-011-9846-7. View

10.

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J . Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12):1090-101. DOI: 10.1056/NEJMoa0908292. View

11.

Xu Y, Wang L, He J, Bi Y, Li M, Wang T . Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310(9):948-59. DOI: 10.1001/jama.2013.168118. View

12.

Landman G, Kleefstra N, van Hateren K, Groenier K, Gans R, Bilo H . Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2009; 33(2):322-6. PMC: 2809274. DOI: 10.2337/dc09-1380. View

13.

Yousef M, Tsiani E . Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies. Cancers (Basel). 2017; 9(5). PMC: 5447955. DOI: 10.3390/cancers9050045. View

14.

Heavey S, OByrne K, Gately K . Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 2013; 40(3):445-56. DOI: 10.1016/j.ctrv.2013.08.006. View

15.

Kurishima K, Satoh H . Prolonged survival in lung cancer patients with diabetes mellitus. J Thorac Oncol. 2012; 7(9):e17-8. DOI: 10.1097/JTO.0b013e3182614877. View

16.

Gullon Blanco J, Toste I, Fernandez Alvarez R, Cuadrado G, Gonzalvez A, Martin I . Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing. 2008; 37(6):715-8. DOI: 10.1093/ageing/afn226. View

17.

Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q . Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017; 317(24):2515-2523. PMC: 5815077. DOI: 10.1001/jama.2017.7596. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

19.

Yang L, Shao J, Bian Y, Wu H, Shi L, Zeng L . Prevalence of type 2 diabetes mellitus among inland residents in China (2000-2014): A meta-analysis. J Diabetes Investig. 2016; 7(6):845-852. PMC: 5089946. DOI: 10.1111/jdi.12514. View

20.

Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S . Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer. 2015; 15:989. PMC: 4685626. DOI: 10.1186/s12885-015-2012-4. View